News
March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial ...
Hosted on MSN1mon
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekShares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved ...
Hosted on MSN1mon
Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeShares of OptiNose (OPTN) have gained 58.6% over the past four weeks to close the last trading session at $9.15, but there could still be a solid upside left in the stock if short-term price ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback